Cytisinicline

Smoking cessation

Manufacturer: Achieve Life Sciences
Regulatory submission: NDA resubmission planned for the fourth quarter of 2026
Launch: Anticipated after potential approval in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

1 evidence topic · 1 source

Pathophysiology

“Nicotine increases dopamine levels, which affect the brain pathways that control reward and pleasure.” (opens the source at this quote in a new tab)